VF
TSHA icon

Virtu Financial’s Taysha Gene Therapies TSHA Stock Holding History

Virtu Financial’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,346
Closed -$60K – 2257
2026
Q1 		$60K Buy
+13,346
New +$62.1K ﹤0.01% 1261
2025
Q4 		– Sell
-48,123
Closed -$157K – 2247
2025
Q3 		$157K Buy
+48,123
New +$136K 0.01% 962
2025
Q1 		– Sell
-107,544
Closed -$186K – 2048
2024
Q4 		$186K Buy
+107,544
New +$223K 0.01% 912
2024
Q3 		– Sell
-57,191
Closed -$128K – 1897
2024
Q2 		$128K Buy
+57,191
New +$166K 0.01% 794
2024
Q1 		– Sell
-26,070
Closed -$46K – 2112
2023
Q4 		$46K Buy
+26,070
New +$52K ﹤0.01% 1187
2023
Q2 		– Sell
-45,459
Closed -$36K – 2052
2023
Q1 		$36K Buy
+45,459
New +$58.7K ﹤0.01% 1152

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Virtu Financial's TSHA Position: Q2 2026 in Review

Virtu Financial sold out of Taysha Gene Therapies (TSHA) in Q2 2026, closing a stake of 13,346 shares — an estimated $60K sold.

Virtu Financial first reported a position in TSHA in Q1 2023 and held it in 6 quarters. The position peaked at $186K in Q4 2024. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Virtu Financial reported no remaining Taysha Gene Therapies position as of Q2 2026 after selling out during the quarter.
  • Virtu Financial sold 13,346 Taysha Gene Therapies shares in Q2 2026, an estimated $60K.
  • Virtu Financial first reported a position in Taysha Gene Therapies in Q1 2023 and held it in 6 quarters.
  • Virtu Financial's Taysha Gene Therapies position peaked at $186K in Q4 2024.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.